In the March 1 issue of The ASCO Post, the article on page 2, “Outcomes Comparable for Panitumumab and Bevacizumab in Metastatic Colorectal Cancer,” contained an inaccuracy about the FDA-approved indications of bevacizumab (Avastin) in colorectal cancer. Specifically, the article noted that bevacizumab is approved for “first-line treatment of patients with wild-type KRAS metastatic colorectal cancer….” In fact, KRAS is not mentioned in any of the drug’s labels.
Bevacizumab’s approved indications in metastatic colorectal cancer are as follows:
First- or second-line treatment of metastatic colorectal cancer in combinations with intravenous fluorouracil–based chemotherapy
In combination with fluoropyrimidine/irinotecan- or fluoropyrimidine/oxaliplatin-based chemotherapy for the second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line bevacizumab-containing regimen
In the March 15 issue of The ASCO Post, the article on page 20, “Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from FDA,” erred as to the trade name of rituximab. The correct product is Rituxan.
We apologize for the errors, both of which have been corrected in the online versions of these articles at ASCOPost.com. ■